Forte Biosciences, Inc. to Review the Second Quarter 2021 Results and Expects to Announce Topline Data From Phase 2 Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis on Sept. 7

Stock Information for Forte Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Forte Biosciences Inc.

Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business Update
ISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company's Upcoming Annual Meeting
Concerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Company's Boardroom
Concerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to Stockholders
Forte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business Update
Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.